Organoid Personalized Therapeutics and the P ancreatic A denocarcinoma S ignature S tratification for treatment (PASS) – 01 trial

• Published in: Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.] 2020-12, Vol.20 (8), p.e16
• Main Authors: Froeling, Fieke EM, Plenker, Dennis, Grainne O’Kane, Aguirre, Andrew J, Wolpin, Brian M, Laheru, Daniel A, Saif, M Wasif, Yu, Kenneth H, Fischer, Sandra, Gallinger, Steven, Knox, Jennifer J, Jaffee, Elizabeth M, Tuveson, David A
• Format: Article
• Language: English
• Subjects: Adenocarcinoma; Biomarkers; Cancer therapies; Chemotherapy; Medical prognosis; Metastasis; Organoids; Pancreatic cancer; Patients; Ribonucleic acid; RNA; Transcriptomics; Tumors
• ISSN: 1424-3903; 1424-3911
• DOI: 10.1016/j.pan.2020.10.008

Keywords: pancreatic cancer, patient-derived organoids, transcriptomic signatures, PASS-01 Background: Patients with advanced pancreatic ductal adenocarcinoma (PDAC) continue to have a dire prognosis and only a minority of patients is fit enough to receive second-line treatment. Secondary and exploratory objectives include determine the objective response rate, duration of response and overall survival associated with mFFX or GA, whether the chemotherapy sensitivity signature predictions correlate with responders, if PDO transcriptomic profiles parallel those obtained from patient samples, whether GATA6 expression can serve as a biomarker of response [4], the use of serial cell free circulating tumor DNA and circulating tumour cell analysis to identify emerging or de novo resistance and evaluate biomarkers of immune-oncologic sensitivity. At progression, as per RECIST 1.1 criteria, chemotherapy sensitivity signatures (RNA) and/or PDO pharmacotyping and WGS data will be used where possible to guide second-line therapy in an effort to continually provide the most active therapeutic regimens to each patient.